文献速递药物不良反应与药物警戒特殊人群用药

门诊成人用复方磺胺甲噁唑-甲氧苄啶的安全性:系统评价与荟萃分析及活性对照药物警戒分析

Safety of sulfamethoxazole-trimethoprim for the treatment of bacterial infection in outpatient settings: A systematic review and meta-analysis with active comparator disproportionality analysis.
PubMed 文献 · Br J Clin Pharmacol · 2025-01-01

该系统评价纳入43项研究,比较成人门诊使用复方磺胺甲噁唑-甲氧苄啶(SMX-TMP)与其他抗生素的不良事件;荟萃分析显示皮疹风险约为其他抗生素的近3倍,药物警戒数据还提示多种皮肤及血液系统等不良事件报告频率更高。

要点

  • SMX-TMP较其他抗生素皮疹风险约高近3倍(汇总RR 2.56)。
  • 药物警戒数据显示皮肤疾病及其他不良事件报告频率高于多种对照药。
  • 仍需更稳健研究确认这些安全信号并指导临床实践。

核心结论

  • 荟萃分析与药物警戒研究提示,SMX-TMP较其他抗生素(包括阿莫西林/克拉维酸、阿奇霉素和呋喃妥因)与更高不良事件风险相关。
  • 需进一步稳健研究确认这些安全信号并指导临床实践。

研究设计与样本

  • 系统评价与荟萃分析:检索MEDLINE和Embase至2024年8月12日,纳入比较成人门诊SMX-TMP与其他抗生素不良事件的43项研究。
  • 药物警戒研究:使用美国FDA不良事件报告系统(FAERS)补充验证荟萃分析发现。

主要发现

  • 皮疹:SMX-TMP较其他抗生素汇总风险比2.56(95%CI 1.69–3.89),I2=0%,n=4458名受试者,来自24项随机对照试验。
  • 药物警戒数据确认皮肤疾病及其他不良事件报告频率高于多种对照药物。
  • 与阿奇霉素相比:Stevens-Johnson综合征报告增加5倍,中毒性表皮坏死松解症增加3倍,伴嗜酸性粒细胞增多和全身症状的药物反应增加10倍。
  • 与阿奇霉素相比:全血细胞减少报告增加10倍,中性粒细胞减少增加6倍,血小板减少与再生障碍性贫血各增加4倍,高钾血症增加56倍,低钠血症增加10倍。

临床怎么用

  • 成人门诊处方SMX-TMP前应评估皮疹及严重皮肤反应风险,并关注血液系统、电解质异常等不良事件监测。
  • 对高风险患者可优先考虑其他抗生素(如阿莫西林/克拉维酸、阿奇霉素、呋喃妥因),但需结合适应证与本地耐药情况。

局限性

  • 原文未报告荟萃分析纳入研究的异质性来源、药物警戒数据的报告偏倚及混杂控制等具体局限信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Sulfamethoxazole-trimethoprim (SMX-TMP) is a widely used antibiotic for treating bacterial infections, but its safety in adult outpatients remains understudied. This systematic review and meta-analysis evaluated the safety profile of SMX-TMP and identified critical research gaps. The pharmacovigilance study aimed to validate and extend findings from meta-analyses to better understand the real-world safety of SMX-TMP. METHODS: We searched MEDLINE and Embase up to 12 August 2024, to identify studies comparing adverse drug events (ADEs) following SMX-TMP vs. other antibiotics in adult outpatients. Meta-analyses were performed where data allowed. A pharmacovigilance study using the Food and Drug Administration Adverse Event Reporting System was conducted to supplement our findings. RESULTS: Our review, which included 43 studies, found SMX-TMP had a nearly 3-fold higher risk of rash compared to other antibiotics (pooled risk ratio 2.56, 95% confidence interval [1.69, 3.89], I2 = 0%, n = 4458 participants, 24 randomized control trials). Pharmacovigilance data confirmed a higher frequencies of skin disorders and other ADEs compared to various comparator drugs. Compared to azithromycin, SMX-TMP was associated with a 5-fold increase in Stevens-Johnson syndrome, a 3-fold increase in toxic epidermal necrolysis, and a 10-fold increase in drug reaction with eosinophilia and systemic symptoms. Additionally, SMX-TMP showed a 10-fold increase in reports of pancytopenia, a 6-fold increase in neutropenia, a 4-fold increase in both thrombocytopenia and aplastic anaemia, a 56-fold increase in hyperkalaemia, and a 10-fold increase in hyponatraemia. CONCLUSION: Our meta-analyses and pharmacovigilance study suggested SMX-TMP was associated with increased risk of ADEs compared to other antibiotics including amoxicillin/clavulanate, azithromycin and nitrofurantoin. Further robust research is essential to confirm these safety signals and guide clinical practice.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Preyra R, Eddin LE, Ahmadi F, et al. Safety of sulfamethoxazole-trimethoprim for the treatment of bacterial infection in outpatient settings: A systematic review and meta-analysis with active comparator disproportionality analysis. Br J Clin Pharmacol. 2025. PMID: 40441678. doi:10.1111/bcp.70051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。